Amgen dumps early-stage CD38xCD3 bispecific, returning rights to Xencor picked up in 2015 alliance

Five years after Amgen $AMGN agreed to wager up to $1.8 billion on an alliance with Xencor that spotlighted their preclinical bispecific T cell engager program directed at CD38 and CD3 for multiple myeloma, the big biotech is walking away from the program. In a review of R&D activities for…

Click to view original post